The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting which will be held 30 May - 03 June 2014 in Chicago, Illinois. Four abstracts will be presented in Oral Abstract Sessions, one in a Poster Highlights Session, and another four in General Poster Sessions.
Oral Abstract Sessions
Abstract # 4500
Monday, 02 June, 9:45 - 9:57, E Hall D1
Cora N. Sternberg, Iwona Skoneczna, J.M.Kerst, Sophie Fossa, Peter Albers, Mads Agerbaek, Herlinde Dumez, Maria De Santis, Christine Theodore, Michael Leahy, J.D. Chester, Antony Verbaeys, Armelle Caty, Gedske Daugaard, Sandrine Marreaud, Samantha Cambier, Richard Sylvester
Final Results of EORTC Intergroup Randomized Phase III Trial Comparing Immediate versus Deferred Chemotherapy after Radical Cystectomy in patients with pT3T4 and/or N+ M0 Transitional Cell Carcinoma of the Bladder.
In this largest reported randomized trial of adjuvant chemotherapy in patients with muscle invasive bladder cancer, immediate adjuvant cisplatin based combination chemotherapy led to a statistically significant improvement in progression-free survival, the secondary endpoint.
Monday, 02 June, 17:12 - 17:24, E Arie Crown Theater
Alexander M. Eggermont, Vanna Chiarion-Sileni, Jean Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo Antonio Ascierto, Jon M. Richards, Celeste Lebbe, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Cyril Konto, Ravichandra Karra Gurunath, Veerle de Pril, Stefan Suciu, Alessandro Testori
Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.
This randomized, multicenter, double-blind phase III trial prospectively assessed the efficacy and safety of ipilimumab in patients who had undergone complete resection of stage III melanoma. At a median follow-up of almost three years, the primary analysis of recurrence-free survival will be presented. Safety data will also be presented.
Monday, 02 June, 8:12 - 8:24, E Arie Crown Theater
Hans-Joachim Schmoll, Karin Haustermans, Timothy Jay Price, Bernard Nordlinger, Ralf Hofheinz, Jean-Francois Daisne, Jozef Janssens, Baruch Brenner, Peter Schmidt, Hans Reinel, Stephan Hollerbach, Karel Caca, Florian W.B. Fauth, Carla Hannig, John Raymond Zalcberg, Niall C. Tebbutt, Murielle E. Mauer, Carlo G. M. Messina, Manfred P. Lutz, Eric Van Cutsem
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: Disease free survival results at interim analysis.
Interim results of this randomized trial indicate that the addition of oxaliplatin to capecitabine plus radiotherapy does not improve disease-free survival in patients with rectal adenocarcinoma.
Sunday, 01 June, 9:12 9:24, E450
Wolfgang Wick, Thierry Gorlia, Martin J. Van Den Bent, Charles J Vecht, Jonathan Steuve, Alba Ariela Brandes, Michael Platten, Markus A Kosch, Monika E. Hegi, Benoit Lhermitte, Vassilis Golfinopoulos, Mario Campone, Jean-Sebastien Frenel, Martin J.B. Taphoorn, Gianfranco A. Pesce, Patrick Roth
Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779)versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.
The study concludes that the therapeutic activity of temsirolimus in patients with newly diagnosed glioblastoma with an unmethylated MGMT promoter is too low.
Poster Highlights Session
Friday, 30 May, 13:00 - 16:00, E354b, Poster Board #25
Divine Ewane Ediebah, Francisca Galindo-Garre, Bernard M.J. Uitdehaag, Jolie Ringash, Jaap C. Reijneveld, Linda Dirven, Efstathios Zikos, Corneel Coens, Martin J. Van Den Bent, Andrew Bottomley, Martin J.B. Taphoorn
Joint modeling of longitudinal health-related quality of life (HRQoL) data and survival.
The findings of this study suggest that part of the survival benefit of radiotherapy plus procarbazine, lomustine and vincristine chemotherapy can be masked by the negative effect that this treatment has on the patients' health related quality of life.
General Poster Sessions
Abstract # 9067
Saturday, 31 May, 8:00 - 11:45. S Hall A2, poster board #271
Stefan Suciu, Natalie Ives, Alexander M. Eggermont, John M. Kirkwood, Paul Lorigan, Svetomir Markovic, Claus Garbe, Keith Wheatley
Predictive importance of ulceration on the efficacy of adjuvant interferon-a: An individual patient data meta-analysis of 15 randomized trials in > 7500 melanoma patients.
This meta-analysis provides evidence that adjuvant interferon significantly reduces the risk of relapse and improves overall survival. It did not identify the optimal dose or duration of interferon, and the overall survival benefit was confined to patients with ulcerated tumors.
Monday, 02 June, 8:00 - 11:45, S Hall A2, Poster Board #287
Isabelle Laure Ray-Coquard, Stefan Sleijfer, Saskia Litière, Jean-Yves Blay, Axel Le Cesne, Zsuzsanna Papai, Ian Robert Judson, Patrick Schoffski, Sant P. Chawla, Thierry Gil, Sophie Piperno-Neumann, Sandrine Marreaud, Rachel Hodge, Winette T.A. Van Der Graaf
Pazopanib in uterine sarcoma: Review of two EORTC & GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma.
Pazopanib shows similar efficacy in uterine sarcomas and non-uterine sarcomas. Median overall survival for uterine sarcoma is longer compared to other subtypes in this small group.
Sunday, 01 June, 8:00 - 11:45. S Hall A2, Poster Board #220
Efstathios Zikos, Corneel Coens, Miriam Sprangers, Eva Greimel, Irina Ghislain, Divine Ewane Ediebah, Henning Flechtner, Andrew Bottomley
Has health-related quality of life assessment in EORTC clinical trials helped to obtain regulatory approvals and change clinical practice? A review of the EORTC experience in cancer clinical trials.
This review demonstrates the major importance of the patient perspective in palliative and curative trials in oncology. It demonstrates how recent findings in EORTC randomized clinical trials have altered clinical practice.
Monday, 02 June, 8:00 - 11:45, S Hall A2, Poster Board #119B
Tryfonidis K., Bogaerts J., Martell R., Sledge G., Balmana J., Audeh W., Deleersnijder A., Favorito F., Agarwal S., Rizzetto G., Messina C., Slaets L., Goulioti T., Tutt A., Cameron D., Turner N.
A phase III randomized trial of niraparib versus physician's choice in previously- treated, HER2 negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.
This trial is currently enrolling patients in Europe, North America, and Israel and is sponsored by TESARO.